Effects of Extra Virgin Olive Oil Polyphenols on Pancreatic Beta-Cell Function and Survival

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 2147-P ◽  
Author(s):  
ANNALISA NATALICCHIO ◽  
ROSARIA SPAGNUOLO ◽  
NICOLA MARRANO ◽  
GIUSEPPINA BIONDI ◽  
LUCIA DIPAOLA ◽  
...  
Plants ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 286
Author(s):  
Nicola Marrano ◽  
Rosaria Spagnuolo ◽  
Giuseppina Biondi ◽  
Angelo Cignarelli ◽  
Sebastio Perrini ◽  
...  

Extra virgin olive oil (EVOO) is a major component of the Mediterranean diet and is appreciated worldwide because of its nutritional benefits in metabolic diseases, including type 2 diabetes (T2D). EVOO contains significant amounts of secondary metabolites, such as phenolic compounds (PCs), that may positively influence the metabolic status. In this study, we investigated for the first time the effects of several PCs on beta-cell function and survival. To this aim, INS-1E cells were exposed to 10 μM of the main EVOO PCs for up to 24 h. Under these conditions, survival, insulin biosynthesis, glucose-stimulated insulin secretion (GSIS), and intracellular signaling activation (protein kinase B (AKT) and cAMP response element-binding protein (CREB)) were evaluated. Hydroxytyrosol, tyrosol, and apigenin augmented beta-cell proliferation and insulin biosynthesis, and apigenin and luteolin enhanced the GSIS. Conversely, vanillic acid and vanillin were pro-apoptotic for beta-cells, even if they increased the GSIS. In addition, oleuropein, p-coumaric, ferulic and sinapic acids significantly worsened the GSIS. Finally, a mixture of hydroxytyrosol, tyrosol, and apigenin promoted the GSIS in human pancreatic islets. Apigenin was the most effective compound and was also able to activate beneficial intracellular signaling. In conclusion, this study shows that hydroxytyrosol, tyrosol, and apigenin foster beta-cells’ health, suggesting that EVOO or supplements enriched with these compounds may improve insulin secretion and promote glycemic control in T2D patients.


Diabetes ◽  
1994 ◽  
Vol 43 (5) ◽  
pp. 718-723 ◽  
Author(s):  
J. Sturis ◽  
I. J. Kurland ◽  
M. M. Byrne ◽  
E. Mosekilde ◽  
P. Froguel ◽  
...  

Diabetes ◽  
1996 ◽  
Vol 45 (11) ◽  
pp. 1572-1579 ◽  
Author(s):  
K. Berkowitz ◽  
R. Peters ◽  
S. L. Kjos ◽  
J. Goico ◽  
A. Marroquin ◽  
...  

2012 ◽  
Vol 2012 ◽  
pp. 1-5 ◽  
Author(s):  
Haoyong Yu ◽  
Ruixia Li ◽  
Lei Zhang ◽  
Haibing Chen ◽  
Yuqian Bao ◽  
...  

CA19-9 is a tumor-associated antigen. It is also a marker of pancreatic tissue damage that might be caused by diabetes. Long-term poor glycemic control may lead to pancreatic beta cell dysfunction which is reflected by elevated serum CA19-9 level. Intracellular cholesterol accumulation leads to islet dysfunction and impaired insulin secretion which provide a new lipotoxic model. This study firstly found total cholesterol was one of the independent contributors to CA19-9. Elevated serum CA19-9 level in diabetic patients may indicate further investigations of glycemic control, pancreatic beta cell function, and total cholesterol level.


PLoS ONE ◽  
2014 ◽  
Vol 9 (12) ◽  
pp. e115433 ◽  
Author(s):  
Donna L. Nile ◽  
Audrey E. Brown ◽  
Meutia A. Kumaheri ◽  
Helen R. Blair ◽  
Alison Heggie ◽  
...  

2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Shivraj Grewal ◽  
Andin Fosam ◽  
Liam Chalk ◽  
Arjun Deven ◽  
Mari Suzuki ◽  
...  

Author(s):  
J Peter Ashby ◽  
Brian M Frier

Pancreatic beta-cell function is usually assessed by the measurement of plasma insulin concentration in various clinical situations. However, the advent of an assay for the measurement of connecting-peptide (C-peptide) concentration in plasma has provided a further method for the assessment of the secretory capacity of the pancreatic beta cell in clinical disorders, particularly in the investigation of hypoglycaemia. The metabolism and immunoassay methodology of C-peptide are reviewed, and its application in clinical practice is outlined.


Sign in / Sign up

Export Citation Format

Share Document